Tango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination.
Common stock authorized rises from 200,000,000 shares. The vote was 85,825,060 for and 11,001,501 against, and the 8-K gives no reason for the larger share count.
The new shelf replaces one that expires on September 12, 2025. Jefferies LLC would earn up to 3.0% on ATM sales, and Tango's stock closed at $1.10 per share on May 8, 2025.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $345.6 million, plus short-term investments of $668.4 million, $1.01 billion in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Tango Therapeutics
Has Tango Therapeutics raised money recently?
Our latest story on this, dated Aug 11, 2026: "Tango Therapeutics files for up to $400,000,000 at-the-market stock program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Tango Therapeutics?
Tango Therapeutics, Inc. trades under the ticker TNGX on NASDAQ.
Where is Tango Therapeutics listed?
Tango Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Tango Therapeutics?
The SEC Central Index Key (CIK) for Tango Therapeutics, Inc. is 1819133. Its filings are on SEC EDGAR.
How many shares does Tango Therapeutics have outstanding?
168,610,367 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Tango Therapeutics listed under?
Our directory records Tango Therapeutics, Inc. under United States.
What does Tango Therapeutics do?
Our directory classifies Tango Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Tango Therapeutics?
The ISIN recorded for Tango Therapeutics, Inc. is US87583X1090.
Does aibio.space cover Tango Therapeutics?
aibio.space lists Tango Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Tango Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Tango Therapeutics's revenue last year?
$62.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Tango Therapeutics profitable?
Tango Therapeutics, Inc. reported a net loss of $101.6 million for the fiscal year ended Dec 31, 2025, and used $138.9 million of cash in operations, per its annual report to the SEC.
How much does Tango Therapeutics spend on research and development?
$132.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Tango Therapeutics have?
$1.01 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Tango Therapeutics (TNGX) stock news?
Our latest story on Tango Therapeutics, dated Aug 11, 2026: "Tango Therapeutics files for up to $400,000,000 at-the-market stock program". Tango Therapeutics filed to sell up to $400,000,000 of stock through Leerink Partners, replacing a $100,000,000 program of which about $64,389,566 had been sold. Its early response rates come from a small group of patients treated in combination. Source.
Investor discussion: Tango Therapeutics
Members talk about Tango Therapeutics (TNGX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Tango Therapeutics, newest first. Each line links the filing it comes from.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:TNGX on TradingView.
SEC filings and registration
SEC name
Tango Therapeutics, Inc.
CIK
1819133
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
TNGX (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
201 BROOKLINE AVENUE, BOSTON, MA, 02215
Phone
(857) 320-4900
Shares outstanding
168,610,367 as of 2026-08-04 (10-Q filed 2026-08-11)
Former names
BCTG Acquisition Corp.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Tango Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TNGX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio